Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Infection Prophylaxis in HSCT
NCT03529825Phase 1Completed
- Sponsor
- Emory University
- Start
- Jul 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rifaximin in bacterial infection and graft-versus-host disease (GVHD) (2 arms), sponsored by Emory University. Primary endpoint: Alterations to microbiome diversity. Started Jul 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
bacterial infectiongraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03529825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529825.